Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

    Research output: Contribution to journalReviewResearchpeer-review

  2. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reply to: "Seasonal variations of lipid profiles in a French cohort"

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 18F-FDG PET/MR-imaging in a Göttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dynamic LED-light versus static LED-light for depressed inpatients: study protocol for a randomised clinical study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.

METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.

RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.

CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.

Original languageEnglish
JournalAtherosclerosis
Volume278
Pages (from-to)97-102
Number of pages6
ISSN0021-9150
DOIs
Publication statusPublished - 1 Nov 2018

ID: 55375594